Detalles de la búsqueda
1.
Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
Diabetes Obes Metab
; 26(3): 997-1007, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38086547
2.
Post hoc analysis of clinical characteristics of patients with radiographic progression in a Japanese phase 3 trial of peficitinib and methotrexate treatment (RAJ4).
Mod Rheumatol
; 33(1): 73-80, 2023 Jan 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35267027
3.
A pooled analysis of serious infections and herpes zoster-related disease in Asian patients with rheumatoid arthritis treated with peficitinib (ASP015K) over a median of 3 years.
Mod Rheumatol
; 32(4): 708-717, 2022 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34918131
4.
A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years.
Mod Rheumatol
; 31(3): 543-555, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33050760
5.
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
Ann Rheum Dis
; 78(10): 1305-1319, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31350269
6.
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
Ann Rheum Dis
; 78(10): 1320-1332, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31350270
7.
Healthcare resource utilization and healthcare costs in patients with type 2 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors vs dipeptidyl peptidase-4 inhibitors in Japan: A real-world administrative database analysis.
J Diabetes Investig
; 15(3): 374-387, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38112598
8.
Cardiometabolic risk reductions in patients with type 2 diabetes mellitus newly treated with a sodium-glucose cotransporter 2 inhibitor versus a dipeptidyl peptidase-4 inhibitor: A real-world administrative database study in Japan.
J Diabetes Investig
; 14(3): 404-416, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36515129
9.
Demographic and clinical characteristics of patients with type 1 diabetes mellitus initiating sodium-glucose cotransporter 2 inhibitors in Japan: A real-world administrative database analysis.
Diabetes Res Clin Pract
; 190: 109973, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35760156
10.
Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis.
Arthritis Res Ther
; 23(1): 221, 2021 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-34429152
11.
Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
Rheumatol Ther
; 8(1): 425-442, 2021 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-33656739
12.
Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Arthritis Res Ther
; 22(1): 47, 2020 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32164762
13.
Correction to: Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
Arthritis Res Ther
; 22(1): 155, 2020 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32576246
14.
Identification of Drug Characteristics for Implementing Multiregional Clinical Trials Including Japan.
Clin Ther
; 40(2): 284-295, 2018 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-29361305
15.
Identification and characterization of VopT, a novel ADP-ribosyltransferase effector protein secreted via the Vibrio parahaemolyticus type III secretion system 2.
Cell Microbiol
; 9(11): 2598-609, 2007 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-17645751
16.
Cytotoxicity and enterotoxicity of the thermostable direct hemolysin-deletion mutants of Vibrio parahaemolyticus.
Microbiol Immunol
; 48(4): 313-8, 2004.
Artículo
en Inglés
| MEDLINE | ID: mdl-15107542
17.
Functional characterization of two type III secretion systems of Vibrio parahaemolyticus.
Infect Immun
; 72(11): 6659-65, 2004 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-15501799
Resultados
1 -
17
de 17
1
Próxima >
>>